Imalia
- Biotech or pharma, therapeutic R&D
Imalia is a Swiss biotech company, developing a breakthrough therapy for sickle cell disease. Our lead asset, IMA001, is a first-in-class small molecule that targets red blood cell metabolism through a novel dual mechanism of action, addressing the root cause of this life-threatening condition.



